title: Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy.
abstract: At present, a constant progress in pathophysiology understanding and treatment of the chronic heart failure (CHF) is arising. The current CHF pharmacotherapy is complex, involving factors affecting the renin-angiotensin-aldosterone system (RAAS), beta-blockers, diuretics and vasodilatators. There are also significant efforts to introduce in CHF pharmacology novel therapeutic strategies, based on the other neurohormonal mechanisms activated in CHF. They include vasopressin receptor antagonists (VRA; vaptans), endothelin receptor antagonists (ERA; sentans), agents relating to the natriuretic peptides system (neutral endopeptidase inhibitors; NEPI and vasopeptidase inhibitors; VPI) and anticytokines agents (anti TNF-alpha immunoglobulin or TNF-alpha scavenger receptor; Etanercept). In this article we briefly describe the modem approach to CHF systemic treatment.
authors.affiliation: Department of Pathophysiology, Jagiellonian University, Medical College 18 Czysta St. 31-121 Kraków, Poland. lukaszd@mp.pl
authors.forename: Łukasz
authors.initials: Ł
authors.lastname: Dobrek
authors.forename: Piotr
authors.initials: P
authors.lastname: Thor
mesh_terms: D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D065128:Endothelin Receptor Antagonists; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors / Q000378:metabolism; D009490:Neurosecretory Systems / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D011480:Protease Inhibitors / Q000627:therapeutic use; D017466:Receptors, Endothelin / Q000378:metabolism; D017483:Receptors, Vasopressin / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D002317:Cardiovascular Agents; D016207:Cytokines; D065128:Endothelin Receptor Antagonists; D006727:Hormone Antagonists; D011480:Protease Inhibitors; D017466:Receptors, Endothelin; D017483:Receptors, Vasopressin; D015260:Neprilysin